NCT04919239CompletedPhase 2
Double-Blind, Randomized, Placebo-Controlled, Phase IIb Clinical Trial to Investigate the Efficacy of RUTI® Therapeutic Vaccination as Adjuvant of Tuberculosis Chemotherapy
Archivel Farma S.L.2 sites in 1 country140 target enrollmentStarted: September 22, 2021Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 140
- Locations
- 2
- Primary Endpoint
- Percentage of patients with Sputum Culture Negative
Study Overview
Brief Summary
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB (Multidrug-resistant) patients favourably responding to standard MDR-TB treatment. Time point of vaccination starts upon completion of 1 week of standard DS-TB treatment (cohort A), and another cohort of patients will be vaccinated upon completion of 1 month of standard MDR-TB treatment (cohort B). All the patients will be followed up to the end of the treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed with pulmonary DS- or MDR-TB, and managed with standard-care TB drugs accordingly;
- •Attending a TB unit / hospital routinely diagnosed with pulmonary DS- or MDR-TB with clinical status ≥ 6 with Bandim TB score combined with chest radiography; and microbiological criteria (MGIT sputum culture), by using rapid genetic testing, gene Xpert;
- •Patients who have not received any anti-tubercular treatment in last 6 months
- •Females and males aged ≥ 18;
- •females of non-childbearing potential: at least 2 years post- menopausal or surgically sterile (e.g. tubal ligation);
- •females of childbearing potential (including females less than 2 years postmenopausal) must have a negative pregnancy test at enrolment and must agree to use highly effective methods of birth control (i.e. diaphragm plus spermicide or male condom plus spermicide, oral contraceptive in combination with a second method, contraceptive implant, injectable contraceptive, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in the study;
- •males must agree to use a double barrier method of contraception (condom plus spermicide or diaphragm plus spermicide) while participating in the study; or the male patient or his female partner must be surgically sterile (e.g. vasectomy, tubal ligation) or the female partner must be post-menopausal;
- •The patient must provide written informed consent;
- •The patient must be willing and able to attend all study visits and comply with all study procedures.
- •Inclusion criteria for vaccination
- •1. Having successfully completed 1 week or 1 month (depending on the cohort) of DS or MDR-TB treatment, respectively, fully supervised; and with beneficial initial response to therapy, evidenced by clinical response.
Exclusion Criteria
- •Inability to provide written informed consent;
- •Women reported, or detected, or willing to be pregnant during the trial period;
- •Severity of illness precluding full evaluation: expected early death, evidenced by respiratory failure, low blood pressure, WHO performance score 3-4
- •Patients with extra-pulmonary tuberculosis
- •Major co-morbid conditions precluding full evaluation, i.e., HIV positive, chronic renal failure, chronic liver failure, Malignancy, patients taking any immunosuppressant drug, active lung cancer, acute coronary syndrome, heart failure exceeding NYHA class 2;
- •Presence of secondary immunodeficiency states: Organ transplantation, diabetes mellitus
- •Any of the following laboratory parameters:
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
- •Total bilirubin > 2 x ULN
- •Neutrophil count ≤ 500 neutrophils / mm3
- •Platelet count < 50,000 cells / mm3
- •Cytotoxic chemotherapy or radiation therapy within the previous 3 months;
- •Blood transfusion in the last three weeks prior to the trial; 10.Patients with history of alcohol or drug abuse
- •11. Documented allergy to TB vaccines, notably, to the RUTI® vaccine
Arms & Interventions
Placebo arm
Placebo Comparator
Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
Intervention: Placebo (Biological)
RUTI® arm
Experimental
A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
Intervention: RUTI® (Biological)
Outcomes
Primary Outcomes
Percentage of patients with Sputum Culture Negative
Time Frame: Up to Week 2 for Cohort A and Month 1.5 for Cohort B
Difference between intervention and control group
Secondary Outcomes
- Proportion of patients with reduction of bacillary load(Up to Week 2 and 8 (Cohort A); and Months 1.5 and 6 (Cohort B))
- Proportion of patients with improvement of clinical signs and symptoms(Up to Week 2 and 8 (Cohort A); and Months 1.5 and 6 (Cohort B))
- Percentage of patients with Sputum Culture Negative(Up to Week 8 for Cohort A and Month 6 for Cohort B)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 2
Safety of RUTI® Vaccination in MDR-TB PatientsTuberculosis, Multidrug ResistantNCT02711735Archivel Farma S.L.9
Completed
Phase 2
A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)Atopic DermatitisNCT04530643Shaperon80
Completed
Phase 1
Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic StrokeAcute StrokeIschemic StrokeStrokeNCT04734548aptaTargets S.L.151
Not yet recruiting
Phase 2
The Androtriol Injection for the Treatment of Acute Ischemic StrokeAcute Ischemic StrokeNCT06679322Beijing Tiantan Hospital300
Completed
Phase 2
A Study of CM310 in Subjects With Moderate to Severe AsthmaAsthmaNCT05186909Keymed Biosciences Co.Ltd52